220 related articles for article (PubMed ID: 24119290)
41. Protein oxidative stress and dyslipidemia in dialysis patients.
Marques de Mattos A; Marino LV; Ovidio PP; Jordão AA; Almeida CC; Chiarello PG
Ther Apher Dial; 2012 Feb; 16(1):68-74. PubMed ID: 22248198
[TBL] [Abstract][Full Text] [Related]
42. Do insulin resistance conditions further impair the lipid and inflammatory profile in end-stage renal disease patients on hemodialysis?
Cacciagiú L; González AI; Elbert A; De'Marziani G; Machida T; Murakami M; López GI; Wikinski R; Nakajima K; Schreier L
Metab Syndr Relat Disord; 2014 May; 12(4):220-6. PubMed ID: 24601848
[TBL] [Abstract][Full Text] [Related]
43. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
44. Correlation between hepcidin level and renal anemia.
Yang LN; Zhang P; Tang F; Wang G; Li FE
Genet Mol Res; 2014 Sep; 13(3):7407-10. PubMed ID: 25222239
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of serum NGAL and hepcidin levels in chronic kidney disease patients.
Avci Çiçek E; Rota S; Dursun B; Kavalci E
Ren Fail; 2016; 38(1):35-9. PubMed ID: 26627016
[TBL] [Abstract][Full Text] [Related]
46. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels.
Preston GA; Barrett CV; Alcorta DA; Hogan SL; Dinwiddie L; Jennette JC; Falk RJ
Nephron; 2002 Dec; 92(4):817-23. PubMed ID: 12399626
[TBL] [Abstract][Full Text] [Related]
47. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Am J Hematol; 2006 Nov; 81(11):832-7. PubMed ID: 16929540
[TBL] [Abstract][Full Text] [Related]
48. A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?
Tessitore N; Poli A; Bedogna V; Corazza L; Campostrini N; Atti M; Sereni L; Castagna A; Girelli D; Pessolano G; Lupo A
J Nephrol; 2018 Apr; 31(2):297-306. PubMed ID: 28353202
[TBL] [Abstract][Full Text] [Related]
49. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance.
Lee SW; Kim JM; Lim HJ; Hwang YH; Kim SW; Chung W; Oh KH; Ahn C; Lee KB; Sung SA
Sci Rep; 2017 Jun; 7(1):4260. PubMed ID: 28652624
[TBL] [Abstract][Full Text] [Related]
50. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
[TBL] [Abstract][Full Text] [Related]
51. Serum hepcidin level and its clinical significance in maintenance hemodialysis patients.
Zhang P; Yang LN; Wang G; Li FE; Tang F
Genet Mol Res; 2014 Nov; 13(4):9883-8. PubMed ID: 25501198
[TBL] [Abstract][Full Text] [Related]
52. [Hyperhomocysteinemia, oxidative stress and microinflammation in chronic renal failure: their roles in atherogene].
Yu YM; Hou FF; Zhang X; Zhou H; Liu ZQ
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):292-5. PubMed ID: 15130417
[TBL] [Abstract][Full Text] [Related]
53. Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients.
Yamamoto M; Matsumoto T; Ohmori H; Takemoto M; Ikeda M; Sumimoto R; Kobayashi T; Kato A; Ohdan H
BMC Nephrol; 2021 Jun; 22(1):221. PubMed ID: 34126941
[TBL] [Abstract][Full Text] [Related]
54. Elevated resistin is related to inflammation and residual renal function in haemodialysed patients.
Malyszko J; Malyszko JS; Kozminski P; Pawlak K; Mysliwiec M
Nephrology (Carlton); 2007 Jun; 12(3):246-53. PubMed ID: 17498119
[TBL] [Abstract][Full Text] [Related]
55. The impact of chronic inflammation on bone turnover in hemodialysis patients.
Eleftheriadis T; Kartsios C; Antoniadi G; Kazila P; Dimitriadou M; Sotiriadou E; Koltsida M; Golfinopoulos S; Liakopoulos V; Christopoulou-Apostolaki M
Ren Fail; 2008; 30(4):431-7. PubMed ID: 18569918
[TBL] [Abstract][Full Text] [Related]
56. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.
Tarakçioğlu M; Erbağci AB; Usalan C; Deveci R; Kocabaş R
Mediators Inflamm; 2003 Feb; 12(1):15-9. PubMed ID: 12745544
[TBL] [Abstract][Full Text] [Related]
57. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
[TBL] [Abstract][Full Text] [Related]
58. Relationship between serum hepcidin levels and cardiovascular disease in patients with maintenance hemodialysis.
Xu Y; Wang Y; Hu H; Li J; Tian T
Physiol Int; 2020 Dec; 107(4):491-500. PubMed ID: 33355540
[TBL] [Abstract][Full Text] [Related]
59. The impact of dialysis type on biomarkers for cardiovascular diseases.
Sahinarslan A; Güz G; Mutluay R; Okyay K; Demirtaş C; Paşaoğlu H; Yalçın R
Turk Kardiyol Dern Ars; 2011 Sep; 39(6):456-62. PubMed ID: 21918314
[TBL] [Abstract][Full Text] [Related]
60. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients.
Oh KH; Jung JY; Yoon MO; Song A; Lee H; Ro H; Hwang YH; Kim DK; Margetts P; Ahn C
Nephrol Dial Transplant; 2010 May; 25(5):1639-46. PubMed ID: 20061317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
